Tina Crow, Individually and on Behalf of Her Husband, Isaac Crow, Jr. v. Bioscript Pharmacy, LLC

CourtLouisiana Court of Appeal
DecidedJuly 15, 2026
Docket56,969-CA
StatusPublished
AuthorRobinson

This text of Tina Crow, Individually and on Behalf of Her Husband, Isaac Crow, Jr. v. Bioscript Pharmacy, LLC (Tina Crow, Individually and on Behalf of Her Husband, Isaac Crow, Jr. v. Bioscript Pharmacy, LLC) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tina Crow, Individually and on Behalf of Her Husband, Isaac Crow, Jr. v. Bioscript Pharmacy, LLC, (La. Ct. App. 2026).

Opinion

Judgment rendered July 15, 2026. Application for rehearing may be filed within the delay allowed by Art. 2166, La. C.C.P.

No. 56,969-CA

COURT OF APPEAL SECOND CIRCUIT STATE OF LOUISIANA

*****

TINA CROW, INDIVIDUALLY Plaintiffs-Appellants AND ON BEHALF OF HER HUSBAND, ISAAC CROW, JR.

versus

BIOSCRIPT PHARMACY, LLC Defendant-Appellee

Appealed from the Twenty-Sixth Judicial District Court for the Parish of Webster, Louisiana Trial Court No. 82,191

Honorable Douglas Stinson, Judge

TINA CROW In Proper Person, Appellant

ISAAC CROW, JR. In Proper Person, Appellant

GORDON, REES, SCULLY, Counsel for Appellee, MANSUKHANI, LLP Option Care Enterprise By: Jay Richard Boltin Andrew George Kimball

Before COX, ROBINSON, and HUNTER, JJ. ROBINSON, J.

Tina Crow (“Mrs. Crow”) filed a pro se petition for damages in forma

pauperis on behalf of her disabled husband, Isaac Crow, Jr. (“Mr. Crow”),

(collectively referred to as “the Crows”), on May 12, 2025, against Bioscript

Pharmacy, LLC (“Bioscript”)1 alleging personal injury to Mr. Crow related

to an overdose of an antibiotic caused by a dosage increase without proper

authorization. Mrs. Crow’s amended petition filed on May 19, 2025, named

Option Care Enterprises, Inc. (“Option Care”) as the proper defendant. The

Crows allege that Mr. Crow later ratified any pleadings filed by Mrs. Crow.

Mrs. Crow filed a motion for default judgment on July 11, 2025.

Option Care filed an exception of prematurity on July 15, asserting the

claims warranted the submission to a medical review panel per the Louisiana

Medical Malpractice Act (“LMMA”). Mrs. Crow filed an opposition to the

exception on July 16. The trial court denied Mrs. Crow’s motion for default

judgment in an interlocutory ruling on July 28. Following a hearing on

October 14, the trial court granted Option Care’s exception of prematurity

and dismissed the case without prejudice, and a final judgment was entered

on November 7. Mrs. Crow appeals.

For the following reasons, we AFFIRM the trial court’s judgment

granting Option Care’s exception of prematurity and dismissing the Crows’

case without prejudice.

1 The original petition filed by Mrs. Crow named BioScript Pharmacy, LLC as the defendant. It is uncertain whether the entity was incorrectly identified or simply misspelled, but presumably Mrs. Crow intended to name BioScrip, Inc. as the defendant. However, due to a merger between BioScrip, Inc., and Option Care, the proper defendant is Option Care, as reflected in the amended petition filed May 19, 2025. FACTS AND PROCEDURAL HISTORY

Mr. Crow was involved in a lawn mower accident in which the tip of

his right middle finger was severed. He suffered complications from his

injury, including gangrene, a bacterial infection, pneumonia, and a cervical

abscess in his neck. He received antibiotic treatment via a peripherally

inserted central catheter (“PICC line”). Mr. Crow ultimately had surgery on

May 29, 2024, to remove the C6 and C7 discs and fuse the C5 and T1 discs.

He continued an antibiotic regimen for osteomyelitis following the surgery.

He was prescribed a low dose of 500 mg daily of the antibiotic Daptomycin

by Dr. Hector Brunet Rodriguez (“Dr. Brunet”) on June 6, 2024, among

other antibiotics and medications, which was administered through the PICC

line by Mrs. Crow during home health treatment. Option Care was the

pharmacy that dispensed Mr. Crow’s medications.

Mr. Crow was seen by Dr. Alexandre Malek (“Dr. Malek”), an

infectious diseases physician, for a follow-up visit on June 20, 2024. He

reported some continued episodes of shortness of breath, but the symptoms

from his condition were otherwise improving. Dr. Malek ordered the

increase of Daptomycin from 500 mg to 750 mg, the recommended dosage

for Mr. Crow’s body weight.

Option Care’s progress notes detail its communications with Mr.

Crow’s physicians and the Crows. On June 20, 2024, an Option Care

pharmacist, Rita Saye (“Ms. Saye”), discussed Mr. Crowe’s IV medications

with Dr. Malek and the increase of Daptomycin from 500 mg to 750 mg

daily. Ms. Saye also discussed the medication increase with Mrs. Crow the

same day and explained that a syringe of the smaller 250 mg dose of

2 Daptomycin would be delivered to them in addition to the 500 mg, since

they had already received the 500 mg dosage. Then, a full 750 mg syringe

would be sent the following week. The additional 250 mg syringe would be

delivered the next day, June 21, to be started that evening. On June 21, Ms.

Saye confirmed again with Mr. Crowe that he was doing the two back-to-

back doses of Daptomycin totaling 750 mg, and he would receive only one

750 mg syringe the next week.

On June 24, Ms. Saye spoke to Mrs. Crow, who reported that Mr.

Crow had been feeling sick since receiving the increased dose of

Daptomycin. She stated that his muscles were weak, he had no energy, and

his mouth had been sore to the point it was difficult to eat. As a result, Mr.

Crow stopped the medication on June 23. Mrs. Crow told Ms. Saye that Mr.

Crow had his labs done that morning, and Ms. Saye responded that she

would let the doctor know about any abnormal results. Mrs. Crow contacted

Option Care the same day to let them know that Mr. Crow’s lab results

showed elevated creatine phosphokinase (“CPK”) levels. Ms. Saye stated

that she had seen the lab results and had already reached out to the doctor

but had not heard back yet. Mrs. Crowe contacted Ms. Saye on June 26 to

inform her that Mr. Crow had seen Dr. Brunet for a follow-up visit and was

feeling better after lowering the Daptomycin dosage. However, Mrs. Crow

notified Ms. Saye on June 28 that Mr. Crow was feeling bad again, and she

would be taking him to the emergency room. Mrs. Crow informed Ms. Saye

on July 2 that Mr. Crow’s lab cultures showed positive results, and she was

told by Dr. Brunet to take him to the hospital. There did not appear to be

3 further communication between the Crows and Option Care past July 2, and

there were no progress notes in the record past July 2024.

Mr. Crow went to the emergency room on June 29. At the time of the

visit, Mr. Crow’s chief complaint was weakness. Mrs. Crow reported to

medical personnel that Mr. Crow’s antibiotic dosage had been increased by

an additional 500 mg, and he started to have body aches, cramps, abdominal

pain, and nausea. As a result, he discontinued the additional dosage. Mr.

Crow’s labs were reviewed by the attending physician, who determined

there were no acute findings, and the weakness complained about could be a

side effect of the antibiotics. Mr. Crow was discharged with instructions to

follow up with the infectious diseases doctor as already scheduled.

Mr. Crow visited the emergency room again on July 2 with concern

over his abnormal labs from July 1. Blood cultures that were taken showed

candida growth, and there were elevated levels of bilirubin and CPK from

the lab dates June 24, June 27, and July 1. The attending physician spoke

with Dr. Brunet, who recommended the continuation of 500 mg of

Daptomycin and the removal of Mr. Crow’s PICC line, which was to be

cultured to determine whether it was the source of the candidemia. Mr.

Crow was admitted to the hospital for the continued IV treatment and

pending CT results to rule out any abscesses. Mr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Howery v. Linton
452 So. 2d 295 (Louisiana Court of Appeal, 1984)
Coleman v. Deno
813 So. 2d 303 (Supreme Court of Louisiana, 2002)
Deville v. Carmouche
450 So. 2d 24 (Louisiana Court of Appeal, 1984)
Gorman v. Miller
136 So. 3d 834 (Louisiana Court of Appeal, 2013)
State v. Wise
182 So. 3d 63 (Louisiana Court of Appeal, 2014)
Root Glass Co. v. Gagliano
124 So. 844 (Louisiana Court of Appeal, 1929)
King v. Illinois Cent. R. R.
131 So. 68 (Louisiana Court of Appeal, 1930)
McElwee v. McElwee
256 So. 2d 477 (Louisiana Court of Appeal, 1972)
Deville v. Orleans Oil Co. of Lafayette
454 So. 2d 420 (Louisiana Court of Appeal, 1984)
Veillon v. Veillon
497 So. 2d 1087 (Louisiana Court of Appeal, 1986)
R & R Steel Erectors v. Watson
809 So. 2d 1228 (Louisiana Court of Appeal, 2002)
Hicks v. Steve R. Reich, Inc.
873 So. 2d 849 (Louisiana Court of Appeal, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Tina Crow, Individually and on Behalf of Her Husband, Isaac Crow, Jr. v. Bioscript Pharmacy, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tina-crow-individually-and-on-behalf-of-her-husband-isaac-crow-jr-v-lactapp-2026.